Predicting treatment outcome and enhancing immunotherapy with anti-PDL1 gold nanoparticles

Rinat Meir; Katerina Shamalov; Cyrille J. Cohen; Rachela Popovtzer

doi:10.1117/12.2509371

7 March 2019 Predicting treatment outcome and enhancing immunotherapy with anti-PDL1 gold nanoparticles

Rinat Meir, Katerina Shamalov, Cyrille J. Cohen, Rachela Popovtzer

Proceedings Volume 10893, Reporters, Markers, Dyes, Nanoparticles, and Molecular Probes for Biomedical Applications XI; 108930Z (2019) https://doi.org/10.1117/12.2509371
Event: SPIE BiOS, 2019, San Francisco, California, United States

Abstract

Immune checkpoint blockade (ICB) has shown unprecedented clinical success in treatment of cancer. However, not all patients show adequate response, and the treatment can lead to a broad range of adverse effects. Therefore, early identification of potential responders to therapy, using non-invasive means, is a critical challenge for improving ICB. Herein, we engineered anti-Programmed Death Ligand 1 (aPDL1) nanoparticles with enhanced ICB immunotherapy efficacy. Using a mouse model for colon cancer, we show that the nanoparticles accumulated, penetrated and efficiently prevented tumor growth. Moreover, we found a direct correlation between the amount of nanoparticle accumulation within the tumor at 48 hours, as determined by CT, and the therapeutic response. This enabled subject stratification as potential responders or non-responders, at an early time point. Thus, by integrating prognostic and ICB-based therapeutic functions into one nanoparticle, we obtained a straightforward approach for potential imageguided stratification of cancer patient subpopulations.

Citation Download Citation

Rinat Meir, Katerina Shamalov, Cyrille J. Cohen, and Rachela Popovtzer "Predicting treatment outcome and enhancing immunotherapy with anti-PDL1 gold nanoparticles", Proc. SPIE 10893, Reporters, Markers, Dyes, Nanoparticles, and Molecular Probes for Biomedical Applications XI, 108930Z (7 March 2019); https://doi.org/10.1117/12.2509371

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available